Lifespan Cancer Institute
Providence, Rhode Island 09206
9 studies enrolling now · 32 studies all time
What they study most
Adolescent, Advanced Breast Cancer, Advanced Cancer, Advanced Solid Tumor, Androgen Receptor Positive, B-cell Non-Hodgkin Lymphoma, Bladder Cancer, Breast Cancer, Breast Cancer Radiation, Breast Neoplasm, Breast Neoplasms, Cancer
Studies at this site
- A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer — Recruiting now
- A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer — Recruiting now
- A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors — Recruiting now
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) — Recruiting now
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer — Recruiting now
- Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens — Recruiting now
- A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors — Recruiting now
- A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) — Recruiting now
- A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors — Recruiting now
- The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer — Running, not enrolling
- CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone — Completed
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Running, not enrolling
- Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction — Running, not enrolling
- CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma — Running, not enrolling
- Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant — Stopped early
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer — Running, not enrolling
- A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma — Completed
- Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL — Running, not enrolling
- Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer — Running, not enrolling
- NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis — Withdrawn before enrolling
- Elevate! : An Elderly Breast Cancer Cohort Study — Running, not enrolling
- A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors — Completed
- I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). — Completed
- Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma — Stopped early
- A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer — Running, not enrolling
- Study of AGEN1571 in Participants With Advanced Solid Tumors — Completed
- Safety of Pregnancy in BRCA Mutated Breast Cancer Patients — Completed
- A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma — Running, not enrolling
- An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma — Stopped early
- TAS-116 Plus Palbociclib in Breast and Rb-null Cancer — Withdrawn before enrolling
- Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer — Completed
- A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM) — Completed